Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris’ federated infrastructure enables participating pharmaceutical companies to use those ...
Leading vascular biologists from Yale, Harvard, Uppsala, and the University of Eastern Finland join Professor Bill Sessa to ...
The new Antibody Developability Consortium will pool proprietary data without exposing members’ sequences, aiming to improve ...
AstraZeneca Puts $2 Billion Behind Summit's Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio / ADC, Akeso ...
The Institute for Protein Innovation (IPI), a nonprofit research organization advancing protein science to accelerate biomedical research and improve human health, today announced the appointment of ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, ...
Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...
(PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, ...
Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or ...
Cell surface protein labeling supports precise characterization of immune checkpoints, receptors, and other therapeutic ...
AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use ...
AstraZeneca Summit investment adds $2 billion and a cancer-trial collaboration. The preferred-equity structure links capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results